Today: 19 May 2026

National Grid share price steadies near 1,390p as UK grid deals and Ofgem deadlines sharpen focus

National Grid share price steadies near 1,390p as UK grid deals and Ofgem deadlines sharpen focus

National Grid shares rose 0.2% to 1,390.5p in early London trading Thursday, following Engie’s £10.5 billion deal for UK Power Networks. Investors are watching Ofgem’s March 2 consultation deadline and National Grid’s May 14 results. Ofgem set the April–June household energy price cap at £1,641, with network costs rising £66.
26 February 2026
····
Experian PLC stock ticks up after buyback trade; May results loom for EXPN

Experian PLC stock ticks up after buyback trade; May results loom for EXPN

Experian shares rose about 1% to 2,688 pence by 0916 GMT Thursday after the company disclosed another round of share buybacks, purchasing 399,433 shares on February 25 for cancellation. The stock remains about 35% below its July 2025 high. Experian’s buyback program, capped at $1 billion, is set to run through June 2027. The company also reported rising fraud losses in EMEA and Asia Pacific in new research.
26 February 2026
··
Glencore stock price slips in London as cobalt-stockpile focus cools

Glencore stock price slips in London as cobalt-stockpile focus cools

Glencore shares fell 1.8% to 524.8 pence in early London trade Thursday, reversing part of Wednesday’s gains. The drop follows news of a $115 million cobalt purchase from Rami Weisfisch for U.S. stockpiles, as cobalt prices surged on Congo export curbs. Copper prices dipped 0.23% on the LME, with inventories at a 13-month high. Glencore’s next shareholder vote is set for May 28, with a Q1 production report due April 30.
26 February 2026
···
Unilever share price drops in early London trade as ULVR turns ex-dividend

Unilever share price drops in early London trade as ULVR turns ex-dividend

Unilever shares fell 0.7% to 5,365 pence in early London trading after going ex-dividend, removing entitlement to the 40.52 pence Q4 payout. The record date is Feb. 27, with cash due April 10. Investors are watching for the company’s Q1 trading statement on April 30. Unilever recently forecast 2026 sales growth at the low end of its range and announced a €1.5 billion buyback.
26 February 2026
··
Rolls-Royce stock in focus: £9 billion buyback plan and profit jump set up a volatile session

Rolls-Royce stock in focus: £9 billion buyback plan and profit jump set up a volatile session

Rolls-Royce announced a £7–£9 billion share buyback for 2026–2028 after reporting a 40% jump in 2025 underlying operating profit to £3.46 billion. The company raised 2026 guidance and declared a final dividend of 5 pence per share, pending shareholder approval. Shares last closed at 1,310 pence. Free cash flow reached £3.3 billion, with net cash at £1.9 billion at year-end.
26 February 2026
·
Xero share price jumps nearly 9% as ASX tech rebounds — May results now in focus

Xero share price jumps nearly 9% as ASX tech rebounds — May results now in focus

Xero shares closed up 8.6% at A$82.30 on Thursday, leading gains in Australian tech after Nvidia’s strong results. The S&P/ASX 200 technology index rose 4.7%, helping the broader market hit a record intraday high. Xero reported Australian small business sales rose 6.7% in the December quarter. Inflation held at 3.8% in January, keeping rate hike expectations in focus.
26 February 2026
··
Fortescue stock price slips after dividend boost — what to watch before ASX reopens

Fortescue stock price slips after dividend boost — what to watch before ASX reopens

Fortescue shares fell 1.4% to A$20.85 on Thursday, reversing part of Wednesday’s 4.7% gain after its half-year results. The miner posted record first-half shipments of 100.2 million tonnes and a net profit of US$1.9 billion. Fortescue raised its interim dividend to A$0.62 a share, with the stock set to go ex-dividend on March 2. Iron ore prices and China steel output cuts remain in focus ahead of policy events.
26 February 2026
··
WiseTech share price jumps again after AI job-cut plan; what ASX traders watch next

WiseTech share price jumps again after AI job-cut plan; what ASX traders watch next

WiseTech Global shares rose 2.6% to A$49.00 Thursday, extending Wednesday’s 11.1% jump after announcing a major AI-driven restructure and cutting 2,000 jobs. Half-year revenue climbed 76% to $672 million, while net profit after tax fell 36% to $68.1 million. The company reaffirmed FY26 guidance. Interim dividend record date is March 16.
26 February 2026
···
CSL share price edges up as buyback keeps ASX heavyweight in play

CSL share price edges up as buyback keeps ASX heavyweight in play

CSL Ltd shares closed up 0.6% at A$146.02 Thursday, near the bottom of their 52-week range. The company disclosed it bought back 79,031 shares Wednesday for about A$11.5 million, bringing total repurchases since September to 3.70 million shares. CSL’s half-year report earlier this month showed a 7% drop in underlying NPATA and US$1.1 billion in after-tax impairments. The stock trades ex-dividend March 10.
26 February 2026
···
Woolworths share price rises again after profit beat; dividend dates and Coles results in focus

Woolworths share price rises again after profit beat; dividend dates and Coles results in focus

Woolworths shares closed up 0.72% at A$36.35 after reporting a 16% rise in first-half underlying net profit to A$859 million, beating estimates. The company raised its full-year earnings outlook and declared a 45-cent fully franked interim dividend. Statutory profit fell 49% to A$374 million after significant items. Investors await Coles’ results on Friday.
26 February 2026
···
Liontown (ASX:LTR) share price slides 8.6% as LG Energy plans stake exit — what traders watch next

Liontown (ASX:LTR) share price slides 8.6% as LG Energy plans stake exit — what traders watch next

Liontown shares fell 8.6% to A$1.815 after LG Energy Solution offered its entire 7.5% stake in a discounted block trade worth at least A$419 million. Trading volume surged to nearly 309 million shares. The final block price was set between A$1.75 and A$1.79 per share. Investors now await shareholder filings and Liontown’s half-year results on March 11.
26 February 2026
··
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 26.02.2026

LIVEMarkets rolling coverageStarted: February 26, 2026, 12:00 AM ESTUpdated: February 26, 2026, 11:59 PM EST Dow, S&P 500, Nasdaq Futures Dip on Nvidia-Led Tech Selloff; NFLX, DUOL, CRWV, XYZ, MARA Active After-Hours February 26, 2026, 11:48 PM EST. U.S. stock futures declined late Thursday as Nvidia's 5.5% post-earnings drop pressured semiconductor stocks, dragging futures lower-Nasdaq 100 futures fell 0.3%, S&P 500 futures 0.4%, and Dow futures 0.6%. Nvidia's slide marked its largest since mid-April amid concerns over rising AI spending commitments, now $95.2 billion, up from $16.1 billion a year earlier, as noted by investor Michael Burry. Despite this, software
26 February 2026
JPMorgan stock price rebounds to $303 as AI jitters ease and traders eye next Fed cues

JPMorgan stock price rebounds to $303 as AI jitters ease and traders eye next Fed cues

JPMorgan shares rose 2.0% to close at $303.30 on Wednesday after executives projected mid-teens percentage growth in first-quarter fees and trading revenue at the bank’s investor day. The stock rebounded from earlier losses, trading between $297.01 and $303.66. Investors now await U.S. jobless claims Thursday and producer prices Friday for further market direction.
26 February 2026
···
1 … 201 202 203 204 205 … 1,952

Stock Market Today

  • When Will Island Pharmaceuticals Limited (ASX:ILA) Reach Profitability?
    May 19, 2026, 3:26 AM EDT. Island Pharmaceuticals Limited (ASX:ILA), a drug repurposing company focusing on antiviral therapeutics in Australia and the U.S., posted a AU$3.9 million loss in the latest financial year and a AU$7.2 million loss over the trailing twelve months. Analysts project the company will break even in 2027 and reach a profit of AU$295 million by 2028. This forecast implies an ambitious average annual growth rate of 140%. Notably, Island Pharmaceuticals operates with no debt, relying solely on shareholder funding, which reduces financial risk typical in cash-burning pharmaceutical firms. Investors anticipate milestone developments but should remain cautious of the high growth assumptions given the volatile nature of pharmaceutical cash flows during drug development phases.

Latest articles

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

19 May 2026
Dominion Energy shares jumped 9.4% after agreeing to an all-stock merger with NextEra Energy, whose shares fell 4.6%. The S&P 500 slipped 0.1% and the Nasdaq dropped 0.5% as investors sold technology stocks amid rising Treasury yields and oil prices. Nvidia fell 1.4% ahead of earnings. U.S. crude settled at $107.37, and the 10-year Treasury yield reached 4.59%.
XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

19 May 2026
XP Inc.’s U.S.-listed shares fell 3.78% in after-hours trading Monday after reporting higher Q1 profit but weaker net inflows and a lower retail take rate. Net income rose 7% to 1.32 billion reais, but net inflow dropped to 14 billion reais from 24 billion a year earlier. The company declared a $0.20 dividend and announced a new CFO, Gustavo Alejo Viviani, starting August 3.
LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

19 May 2026
Publicis Groupe agreed to buy LiveRamp Holdings for $38.50 a share in cash, valuing the U.S. data-collaboration firm at $2.546 billion. LiveRamp stock jumped to $37.77 on the news, while the broader market fell. LiveRamp reported fiscal Q4 revenue of $206 million, up 9% from a year earlier. Publicis said the deal will boost its adjusted earnings per share from the first year after closing.

Popular

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

19 May 2026
Regeneron Pharmaceuticals shares fell 9.8% to $629.68 Monday after its late-stage melanoma drug trial with fianlimab failed to meet the main goal. The study did not show a statistically significant benefit over Merck’s Keytruda. At least 10 brokerages cut price targets. The decline outpaced broader market losses, with the Nasdaq down 0.5%.
Go toTop